European regulators have come out in favor of adapted monovalent COVID-19 vaccines targeting the XBB strains of the SARS-CoV-2 virus that have become dominant in Europe and other parts of the world.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?